Spanish dermatology specialist Almirall was trading 3% lower at lunchtime on Monday after the presentation of its latest financial results. 25 July 2022
The UK’s pricing and reimbursement agency, the National Institute for Health and Care Excellence (NICE), has issued its verdict on new atopic dermatitis treatme 5 July 2022
Belgian drugmaker UCB was trading 4% lower on Friday afternoon as markets digests its acceptance of the need to revise its 2022 financial guidance to a more pes 24 June 2022
The US Food and Drug Administration has approved Dupixent (dupilumab) for certain children, aged six months to five years, with moderate-to-severe atopic dermat 8 June 2022
Spanish dermatology specialist Almirall (BME: ALM) announced topline results from one-year analyses of the efficacy and safety of lebrikizumab, an investigation 7 June 2022
Spanish dermatology specialist Almirall (BME: ALM) looked set to close Monday’s trading around 10% lower after presenting its first quarter financial results. 9 May 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.